Example: Heart Attack

Search clinical trials for: Treprostinil

Total 109 results

NCT04309838

Not yet recruiting

Observation Study With Implantable Medication Pump for Intravenous Treprostinil Therapy in Patients With Pulmonary Arterial Hypertension

Conditions: Pulmonary Arterial Hypertension; PAH
NCT04062565

Recruiting

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

Conditions: Pulmonary Arterial Hypertension
NCT04041648

Recruiting

Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606

Conditions: Pulmonary Arterial Hypertension
NCT04005469

Not yet recruiting

Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation

Conditions: Ischemia Reperfusion Injury; Delayed Graft Function
NCT03992755

Active, not recruiting

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

Conditions: Primary Pulmonary Hypertension
NCT03950739

Recruiting

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

Conditions: Pulmonary Arterial Hypertension
NCT03888365

Completed

Patient Global Impression Questions for Activity-induced Symptoms in Patients With PAH

Conditions: Pulmonary Arterial Hypertension
NCT03884465

Active, not recruiting

Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil

Conditions: Pulmonary Arterial Hypertension
NCT03835676

Recruiting

Effects of Treprostinil on Right Ventricular Structure and Function in Patients With Pulmonary Arterial Hypertension

Conditions: Pulmonary Hypertension
NCT03833323

Not yet recruiting

Implantable System for Remodulin Post-Approval Study

Conditions: Pulmonary Arterial Hypertension
NCT03814317

Recruiting

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

Conditions: Sarcoidosis; Precapillary Pulmonary Hypertension; Interstitial Lung Disease
NCT03803163

Terminated

A Safety, Tolerability and Pharmacokinetics Study of TransCon Treprostinil in Healthy Adult Male Volunteers

Conditions: Healthy Volunteers
NCT03794583

Enrolling by invitation

Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)

Conditions: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease
NCT03654989

Recruiting

Iontophoresis of Treprostinil to Enhance Wound Healing in Diabetic Foot Skin Ulcers

Conditions: Diabetic Foot Ulcer
NCT03497689

Recruiting

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

Conditions: Pulmonary Arterial Hypertension
NCT03496623

Recruiting

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With PH Due to COPD

Conditions: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease
NCT03464864

Completed

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

Conditions: Pulmonary Arterial Hypertension
NCT03399604

Active, not recruiting

Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil

Conditions: Primary Pulmonary Hypertension
NCT03120533

Completed

Treprostinil Iontophoresis in Systemic Sclerosis Digital UlcErations. A Proof of Concept Study

Conditions: Scleroderma, Systemic
NCT03055221

Completed

TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)

Conditions: Pulmonary Arterial Hypertension
NCT03055234

Withdrawn

Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)

Conditions: Pulmonary Hypertension Associated With Sickle Cell Disease
NCT03045029

Recruiting

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

Conditions: Pulmonary Arterial Hypertension
NCT03043651

Terminated

Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)

Conditions: Pulmonary Hypertension Associated With HFpEF
NCT03037580

Terminated

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction

Conditions: Pulmonary Hypertension; Heart Failure With a Preserved Ejection Fraction
NCT03016468

Withdrawn

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

Conditions: Pulmonary Arterial Hypertension
NCT03012646

Withdrawn

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

Conditions: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease
NCT02999906

Withdrawn

Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

Conditions: Pulmonary Arterial Hypertension
NCT02893995

Withdrawn

Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

Conditions: Pulmonary Arterial Hypertension
NCT02889315

Unknown status

LenusPro Pump in PAH Treated With Treprostinil

Conditions: Pulmonary Arterial Hypertension
NCT02882126

Withdrawn

An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension

Conditions: Pulmonary Arterial Hypertension
NCT02865733

Unknown status

Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery

Conditions: Pulmonary Hypertension
NCT02847260

Completed

Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)

Conditions: Pulmonary Arterial Hypertension
NCT02770521

Completed

A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants

Conditions: Healthy
NCT02769624

Terminated

Acute Effects of Inhaled Treprostinil in Fontan Patients

Conditions: Congenital Heart Disease
NCT02663895

Completed

Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis

Conditions: Systemic Sclerosis; Calcinosis
NCT02633293

Active, not recruiting

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

Conditions: Pulmonary Hypertension; Interstitial Lung Disease; Combined Pulmonary Fibrosis and Emphysema
NCT02630316

Completed

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

Conditions: Pulmonary Hypertension; Interstitial Lung Disease; Combined Pulmonary Fibrosis and Emphysema
NCT02603068

Withdrawn

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Conditions: Pulmonary Hypertension; Pulmonary Fibrosis
NCT02583789

Recruiting

Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon

Conditions: Raynaud's Phenomenon
NCT02498444

Active, not recruiting

Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation

Conditions: Single Ventricle
NCT02471183

Completed

Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension

Conditions: Pulmonary Arterial Hypertension
NCT02370095

Terminated

Treprostinil Sodium Inhalation for Patients At High Risk for ARDS

Conditions: Respiratory Distress Syndrome, Adult
NCT02318186

Completed

Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH)

Conditions: Pulmonary Arterial Hypertension
NCT02318758

Completed

Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers

Conditions: Healthy
NCT02276872

Completed

Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years

Conditions: PAH
NCT02261883

Recruiting

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Conditions: Persistent Pulmonary Hypertension of the Newborn
NCT02178566

Terminated

Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
NCT02149095

Withdrawn

Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers

Conditions: PAH
NCT02074449

Completed

Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)

Conditions: Pulmonary Arterial Hypertension
NCT01980979

Withdrawn

Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

Conditions: Congenital Heart Disease

Search clinical trials for: Treprostinil

Recent CRA jobs

Medical Technologist, Central labs

Clinical Team Manager

Manager, Clinical Data Management

Lab Support Tech

Clinical Trial Coordinator

Principal Programmer Analyst

Digital Project Specialist I

Scientist Biopharm - HPLC (IEX , SEC )

Project Manager - Labs (Metrology)

Director, Project Management - Respiratory Diseases Team